Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

Modulation of myeloid and T cells in vivo by Bruton's tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma

The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications, Molecular Cancer

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective. - Abstract - Europe PMC

Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells

Pharmaceutics, Free Full-Text

Sulfonamides as tyrosine kinase modulators – A promising class of anticancer agents - ScienceDirect

Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment, Journal of Experimental & Clinical Cancer Research

Cancers, Free Full-Text

Biomedicines, Free Full-Text

Targeting Myeloid-Derived Suppressor Cell, a Promising Strategy to Overcome Resistance to Immune Checkpoint Inhibitors. - Abstract - Europe PMC